The world at large cannot afford to miss even a single case of COVID-19 because of its far-reaching consequences; therefore, the diagnostic development to achieve test with much higher sensitivity should be made available at a mass level as early as possible.
FDA permits marketing of first SARS-CoV-2 diagnostic test using traditional premarket review process FDA. 2021 (accessed 2 May 2021).
Arevalo-Rodriguez I, Buitrago-Garcia D, Simancas-Racines D, Zambrano-Achig P, del Campo R, Ciapponi A, et al. False-negative results of initial RT-PCR assays for COVID-19: a systematic review. medRxiv. 2020. DOI: 10.1101/2020.04.16.20066787.
Kinloch NN, Ritchie G, Brumme CJ, Dong W, Dong W, Lawson T, et al. Suboptimal biological sampling as a probable cause of false-negative COVID-19 diagnostic test results. J Infect Dis 2020;222(6):899–902. DOI: 10.1093/infdis/jiaa370.
Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure. Ann Intern Med 2020;173(4):262–267. DOI: 10.7326/M20-1495.
Prinzi A. False negatives and reinfections: the challenges of SARS-CoV-2 RT-PCR testing. https://asm.org/Articles/2020/April/False-Negatives-and-Reinfections-the-Challenges-of (accessed 5 July 2020).